Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean F Bajorin

Showing results (61-70 of 169) with videos related to

Pageof 17
Sort By:
International Journal of Cancer|August 10, 2004
Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patientsIman Osman, Melissa Kang, Andy Lee, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 9, 2017
Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder
Shaheen R Alanee, Sohela Shah, Emily C Zabor, et al.
Urology|April 29, 2018
Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell TumorEugene J Pietzak, Melissa Assel, Maria F Becerra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancerArjun V Balar, Andrea B Apolo, Irina Ostrovnaya, et al.
BJU International|August 17, 2010
Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implicationsSatish K Tickoo, Matthew I Milowsky, Nitin Dhar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2007
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumorsRobert J Motzer, Craig J Nichols, Kim A Margolin, et al.
Bladder Cancer (Amsterdam, Netherlands)|May 19, 2017
Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma <i>In Situ</i> of the Bladder who failed Bacillus Calmette Guerin (NCT01259063)Guido Dalbagni, Nicole Benfante, Daniel D Sjoberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2022
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)Jonathan E Rosenberg, Se Hoon Park, Vadim Kozlov, et al.
The Journal of Urology|February 13, 2014
Clinical outcomes of local and metastatic testicular sex cord-stromal tumorsJonathan L Silberstein, Wassim M Bazzi, Emily Vertosick, et al.
Journal of Oncology Practice|January 21, 2014
Where do patients with cancer in Iowa receive radiation therapy?Marcia M Ward, Fred Ullrich, Kevin Matthews, et al.
Pageof 17

Showing results (61-70 of 169) with videos related to

Sort By:
Pageof 17
International Journal of Cancer|August 10, 2004
Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patientsIman Osman, Melissa Kang, Andy Lee, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 9, 2017
Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder
Shaheen R Alanee, Sohela Shah, Emily C Zabor, et al.
Urology|April 29, 2018
Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell TumorEugene J Pietzak, Melissa Assel, Maria F Becerra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancerArjun V Balar, Andrea B Apolo, Irina Ostrovnaya, et al.
BJU International|August 17, 2010
Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implicationsSatish K Tickoo, Matthew I Milowsky, Nitin Dhar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2007
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumorsRobert J Motzer, Craig J Nichols, Kim A Margolin, et al.
Bladder Cancer (Amsterdam, Netherlands)|May 19, 2017
Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma <i>In Situ</i> of the Bladder who failed Bacillus Calmette Guerin (NCT01259063)Guido Dalbagni, Nicole Benfante, Daniel D Sjoberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2022
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)Jonathan E Rosenberg, Se Hoon Park, Vadim Kozlov, et al.
The Journal of Urology|February 13, 2014
Clinical outcomes of local and metastatic testicular sex cord-stromal tumorsJonathan L Silberstein, Wassim M Bazzi, Emily Vertosick, et al.
Journal of Oncology Practice|January 21, 2014
Where do patients with cancer in Iowa receive radiation therapy?Marcia M Ward, Fred Ullrich, Kevin Matthews, et al.
Pageof 17